Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04965792 · ClinicalTrials.gov registry record
Post-treatment Surveillance in HPV+ Oropharyngeal SCC
A clinical trial of Hpv and Oropharyngeal Squamous Cell Carcinoma, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT04965792 is a study of Hpv and Oropharyngeal Squamous Cell Carcinoma that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 150 participants, below the 2,235-participant average among 24 other Hpv trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04965792, a study of Hpv and Oropharyngeal Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
In this research study the investigators are examining a blood test to detect HPV DNA in the blood that can possibly detect cancer recurrence earlier than with standard surveillance measures.
Conditions Studied
Interventions
- OTHER Screening
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2020-11-19 |
| Est. Completion | 2027-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04965792
The ClinicalTrials.gov registry entry for NCT04965792 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,235-participant average among 24 other Hpv trials with a reported enrollment target (93% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hpv appearing as the primary indexed condition, and to 1 intervention - of which Screening is the first listed.
NCT04965792 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04965792 about?
NCT04965792 is a clinical study titled "Post-treatment Surveillance in HPV+ Oropharyngeal SCC". In this research study the investigators are examining a blood test to detect HPV DNA in the blood that can possibly detect cancer recurrence earlier than with standard surveillance measures.
What is the current status of trial NCT04965792?
This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2020-11-19. Estimated completion is 2027-11.
What conditions does trial NCT04965792 study?
This clinical trial studies the following conditions: Hpv, Oropharyngeal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT04965792?
The interventions under investigation include: Screening (OTHER).
Who is sponsoring clinical trial NCT04965792?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04965792 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hpv
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
Stand Up 2 HPV: Standing Orders to Improve HPV Vaccination
RECRUITING · NA
-
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
RECRUITING · Phase 2
-
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
RECRUITING
-
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
RECRUITING · Phase 2
-
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.